TABLE 2.

Dosimetry for CSF and Ventricles After Intracranioventricular Administration of ¹³¹I-Omburtamab in 95 Patients

Age group	CSF		Ventricles		Blood^* (absorbed dose [mGy/MBq])	Whole body
Age group	Absorbed dose (cGy/MBq)	Clearance (h)	Absorbed dose (cGy/MBq)	Clearance (h)	Blood^* (absorbed dose [mGy/MBq])	Absorbed dose (mGy/MBq)	Clearance (h)
<5 y, n = 34	0.50 ± 0.18 (0.29–1.12)	10.6 ± 11.7 (5.8–74.6)	1.13 ± 0.96 (0.30–5.15)	7.0 ± 2.3 (3.4–14.0)	0.63 ± 0.37 (0.12–1.57)	0.67 ± 0.31 (0.07–1.41)	41.2 ± 10.2 (25.2–65.0)
5–10 y, n = 31	0.52 ± 0.21 (0.24–1.06)	9.4 ± 2.9 (5.5–19.2)	1.01 ± 0.55 (0.38–2.47)	8.0 ± 3.0 (3.8–15.7)	0.67 ± 0.54 (0.10–2.30)	0.46 ± 0.26^† (0.05–1.43)	40.6 ± 7.5 (25.8–61.0)
>10 y, n = 30	0.90 ± 0.52^† (0.24–2.25)	19.1 ± 13.2^† (7.8–57.8)	0.95 ± 0.41 (0.27–1.92)	8.3 ± 2.7^† (4.3–17.2)	0.30 ± 0.40^† (0.03–1.45	0.20 ± 0.16^† (0.05–0.66)	42.3 ± 14.3 (22.6–80.8)
All, n = 95^*	0.63 ± 0.38 (0.24–2.25)	13.0 ± 10.9 (5.5–74.6)	1.03 ± 0.69 (0.27–5.15)	7.7 ± 2.6 (3.4–17.2)	0.54 ± 0.46 (0.03–2.30)	0.45 ± 0.32 (0.05–1.43)	41.3 ± 10.9 (22.6–80.8)

↵* Blood data were available for n = 24, 20, and 21 patients in 3 age groups.
↵† Significant difference with respect to <5-y group based on Mann–Whitney U test for unpaired 2-sample data.
Data are median and range.